On this page
Nystatin and Triamcinolone Acetonide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 208479-001 | NYSTATIN AND TRIAMCINOLONE ACETONIDE | CREAM | NYSTATIN; TRIAMCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | August 14, 2017 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260112). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Nystatin and Triamcinolone Acetonide Cream is usually applied to the affected areas twice daily in the morning and evening by gently and thoroughly massaging the preparation into the skin. The cream should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). A thin film of Nystatin and Triamcinolone Acetonide Ointment is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). Nystatin and Triamcinolone Acetonide Cream and Ointment should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies. Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur. The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Crown Laboratories, Inc. at 1-423-926-4413 or FDA at 1-800-FDA-1088 or https://www.fda.gov/Safety/MedWatch/
Description
openFDA Drug LabelingDESCRIPTION Nystatin and Triamcinolone Acetonide Cream, USP for dermatologic use contains the antifungal agent nystatin, USP and the synthetic corticosteroid triamcinolone acetonide, USP. Nystatin, USP is a polyene antimycotic obtained from Streptomyces noursei . It is a yellow to light tan, hygroscopic powder, having a bitter taste and an odor suggestive of cereals. It is freely soluble in dimethylformamide and dimethyl sulfoxide; slightly to sparingly soluble in methanol, n-propyl alcohol, and n-butyl alcohol; practically insoluble in water and alcohol; insoluble in chloroform and ether. Structural formula: C 47 H 75 NO 17 ; MW = 926.11 g/mol Triamcinolone acetonide, USP is designated chemically as pregna-1, 4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)-9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone. The white to cream colored, crystalline powder, having not more than a slight odor, is practically insoluble in water, sparingly soluble in dehydrated alcohol, in chloroform and in methanol. Structural formula: C 24 H 31 FO 6 ; MW = 434.50 g/mol Nystatin and Triamcinolone Acetonide Cream, USP is a soft, smooth yellow color cream. Each gram provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide, USP in a cream base with dried aluminum hydroxide gel, glyceryl monostearate, methylparaben, polyethylene glycol 400 monostearate, polyoxyl 20 cetostearyl ether, polysorbate-60, propylene glycol, propylparaben, purified water, simethicone emulsion, sorbic acid, sorbitol, titanium dioxide, and white petrolatum. nystatin-image triamcinolone-structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General) ; however, acute overdosage and serious adverse effects with dermatologic use are unlikely.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin and triamcinolone acetonide cream USP supplied in 15 gram, 30 gram and 60 gram tubes. 15 gram Tube NDC 33342-482-15 (1 tube per carton) 30 gram Tube NDC 33342-482-30 (1 tube per carton) 60 gram Tube NDC 33342-482-60 (1 tube per carton) STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid freezing. Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer by: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA Rev. 09/2023
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class III | July 31, 2019 | Lupin Pharmaceuticals Inc. | Failed Content Uniformity Specifications: Out-of-specification result observed in uniformity of containers test at 9 month long term stability condition for upright orientation. | Terminated |
| Class II | April 26, 2017 | Taro Pharmaceuticals U.S.A., Inc. | Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 62332-606-15 | 62332-606 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-606-15) / 15 g in 1 TUBE | April 2, 2021 |
| 62332-606-30 | 62332-606 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-606-30) / 30 g in 1 TUBE | April 2, 2021 |
| 62332-606-60 | 62332-606 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-606-60) / 60 g in 1 TUBE | April 2, 2021 |
| 46708-606-15 | 46708-606 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-606-15) / 15 g in 1 TUBE | April 8, 2025 |
| 46708-606-30 | 46708-606 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-606-30) / 30 g in 1 TUBE | April 8, 2025 |
| 46708-606-60 | 46708-606 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-606-60) / 60 g in 1 TUBE | April 8, 2025 |
| 63629-8688-1 | 63629-8688 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8688-1) / 15 g in 1 TUBE | November 27, 2017 |
| 63629-8689-1 | 63629-8689 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8689-1) / 30 g in 1 TUBE | November 27, 2017 |
| 63629-8690-1 | 63629-8690 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8690-1) / 60 g in 1 TUBE | November 27, 2017 |
| 71335-2894-1 | 71335-2894 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2894-1) / 30 g in 1 TUBE | October 28, 2025 |
| 72162-1433-2 | 72162-1433 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1433-2) / 15 g in 1 TUBE | March 11, 2024 |
| 72162-1433-3 | 72162-1433 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1433-3) / 30 g in 1 TUBE | April 23, 2025 |
| 72162-1433-6 | 72162-1433 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1433-6) / 60 g in 1 TUBE | March 11, 2024 |
| 0316-0223-15 | 0316-0223 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0223-15) / 15 g in 1 TUBE | January 2, 2018 |
| 0316-0223-30 | 0316-0223 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0223-30) / 30 g in 1 TUBE | January 2, 2018 |
| 0316-0223-60 | 0316-0223 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0223-60) / 60 g in 1 TUBE | January 2, 2018 |
| 68462-314-17 | 68462-314 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-314-17) / 15 g in 1 TUBE | October 25, 2016 |
| 68462-314-35 | 68462-314 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-314-35) / 30 g in 1 TUBE | October 25, 2016 |
| 68462-314-65 | 68462-314 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-314-65) / 60 g in 1 TUBE | October 25, 2016 |
| 68180-545-02 | 68180-545 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-545-02) / 30 g in 1 TUBE | November 29, 2018 |
| 68180-545-03 | 68180-545 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-545-03) / 60 g in 1 TUBE | November 29, 2018 |
| 33342-482-15 | 33342-482 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-482-15) / 15 g in 1 TUBE | August 31, 2022 |
| 33342-482-30 | 33342-482 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-482-30) / 30 g in 1 TUBE | August 31, 2022 |
| 33342-482-60 | 33342-482 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-482-60) / 60 g in 1 TUBE | August 31, 2022 |
| 68071-3972-3 | 68071-3972 | NuCare Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68071-3972-3) / 30 g in 1 TUBE | March 2, 2026 |
| 68071-2491-3 | 68071-2491 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-2491-3) / 30 g in 1 TUBE | August 4, 2021 |
| 68071-5037-3 | 68071-5037 | NuCare Pharmaceuticals,Inc. | 30 g in 1 TUBE (68071-5037-3) | August 21, 2019 |
| 45802-880-14 | 45802-880 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-880-14) / 15 g in 1 TUBE | November 27, 2017 |
| 45802-880-94 | 45802-880 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-880-94) / 30 g in 1 TUBE | November 27, 2017 |
| 45802-880-96 | 45802-880 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-880-96) / 60 g in 1 TUBE | November 27, 2017 |
| 68788-8662-3 | 68788-8662 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8662-3) / 30 g in 1 TUBE | May 13, 2024 |
| 68788-8808-3 | 68788-8808 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8808-3) / 30 g in 1 TUBE | January 20, 2025 |
| 68788-8245-3 | 68788-8245 | Preferred Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68788-8245-3) / 30 g in 1 TUBE | August 18, 2022 |
| 70518-1114-0 | 70518-1114 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-1114-0) / 30 g in 1 TUBE | April 12, 2018 |
| 51672-1263-1 | 51672-1263 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1263-1) / 15 g in 1 TUBE | December 22, 1987 |
| 51672-1263-2 | 51672-1263 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1263-2) / 30 g in 1 TUBE | December 22, 1987 |
| 51672-1263-3 | 51672-1263 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1263-3) / 60 g in 1 TUBE | December 22, 1987 |
| 13668-610-01 | 13668-610 | Torrent Pharmaceuticals Limited | 1 TUBE in 1 CARTON (13668-610-01) / 15 g in 1 TUBE | July 14, 2020 |
| 13668-610-02 | 13668-610 | Torrent Pharmaceuticals Limited | 1 TUBE in 1 CARTON (13668-610-02) / 30 g in 1 TUBE | July 14, 2020 |
| 13668-610-05 | 13668-610 | Torrent Pharmaceuticals Limited | 1 TUBE in 1 CARTON (13668-610-05) / 60 g in 1 TUBE | July 14, 2020 |
| 62332-606 | 62332-606 | Alembic Pharmaceuticals Inc. | — | April 2, 2021 |
| 46708-606 | 46708-606 | Alembic Pharmaceuticals Limited | — | April 8, 2025 |
| 63629-8688 | 63629-8688 | Bryant Ranch Prepack | — | November 27, 2017 |
| 63629-8689 | 63629-8689 | Bryant Ranch Prepack | — | November 27, 2017 |
| 63629-8690 | 63629-8690 | Bryant Ranch Prepack | — | November 27, 2017 |
| 71335-2894 | 71335-2894 | Bryant Ranch Prepack | — | November 27, 2017 |
| 72162-1433 | 72162-1433 | Bryant Ranch Prepack | — | November 27, 2017 |
| 0316-0223 | 0316-0223 | Crown Laboratories | — | January 2, 2018 |
| 68462-314 | 68462-314 | Glenmark Pharmaceuticals Inc., USA | — | October 24, 2016 |
| 68180-545 | 68180-545 | Lupin Pharmaceuticals, Inc. | — | November 29, 2018 |
| 33342-482 | 33342-482 | Macleods Pharmaceuticals Limited | — | August 31, 2022 |
| 68071-3972 | 68071-3972 | NuCare Pharmaceuticals, Inc. | — | August 31, 2022 |
| 68071-2491 | 68071-2491 | NuCare Pharmaceuticals,Inc. | — | November 27, 2017 |
| 68071-5037 | 68071-5037 | NuCare Pharmaceuticals,Inc. | — | December 22, 1987 |
| 45802-880 | 45802-880 | Padagis Israel Pharmaceuticals Ltd | — | November 27, 2017 |
| 68788-8662 | 68788-8662 | Preferred Pharmaceuticals Inc. | — | May 13, 2024 |
| 68788-8808 | 68788-8808 | Preferred Pharmaceuticals Inc. | — | January 20, 2025 |
| 68788-8245 | 68788-8245 | Preferred Pharmaceuticals Inc., USA | — | August 18, 2022 |
| 70518-1114 | 70518-1114 | REMEDYREPACK INC. | — | April 12, 2018 |
| 51672-1263 | 51672-1263 | Sun Pharmaceutical Industries, Inc. | — | December 22, 1987 |
| 13668-610 | 13668-610 | Torrent Pharmaceuticals Limited | — | July 14, 2020 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.